The U.S. Patent and Trademark Office (USPTO) has announced a significant extension of the IP5 Patent Prosecution Highway (PPH) pilot ...
Pharmaceuticals underperformed the S&P 500 in 2023 but have been outperforming the broader market in 2024. The PPH fund offers exposure to pharmaceutical stocks and has outperformed its peers in terms ...
“PPH requests appear to have been filed for less than 1% of U.S. applications. Why are applicants foregoing the program? While the program does not require payment of a fee per se, the author proposes ...
VanEck Pharmaceutical ETF offers focused exposure to large-cap pharmaceutical companies, benefiting from strong long-term demographic and innovation trends. PPH's high concentration in top holdings ...
24/7 Wall St. on MSN
VanEck pharmaceutical fund bets big on weight-loss drug market approaching $150 billion
Quick Read VanEck Pharmaceutical ETF (PPH) surged 26% over the past year driven by weight-loss drug demand. Eli Lilly and Novo Nordisk combine for 27% of holdings. Analysts expect the GLP-1 market to ...
Below is Validea's ETF fundamental report for VanEck Pharmaceutical ETF (PPH). The report looks at PPH's exposure to the major investing factors including value, quality, momentum and low volatility.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results